Nintedanib, which suppresses the production of fibrosis-related factor receptors such as vascular endothelial growth factor (VEGF), fibroblast growth factor (FGF), and platelet-derived growth factor (PDGF), is approved as a treatment medication for patients with idiopathic pulmonary fibrosis. This evidence concerns the gene VEGFA and pulmonary fibrosis.